Supplementary file

Published: 29 April 2024| Version 1 | DOI: 10.17632/hmyd3m5yfw.1
Contributors:
Kexiang Yan, Ling Han, Zhenghua Zhang, Fuqiu Li, Xiaodong Bi, Rixing Chen, Yuye Li, Litao Zhang, Xiaohua Wang, Linfeng Li, Jianyun Lu, Aie Xu, Sen Yang, Yan Lu, Jiangfang Sun, Zhiming Li, Xiaohong Zhu, Meiying Jiang, Siping Zhang, Wenqing Wang, Yanling Li, Zudong Meng, Hongyi Li, Kuanhou Mu, Xiuping Han, Shanshan Li, Ai-Jun Chen, Xin Li, Donghua Liu, Chunlei Zhang, Chao Ji, wang yu, Hao Cheng, Xiaojing Cui, Xiaoyan Yao, Xiaoyan Bai, Guangchao Dong, Jinhua Xu

Description

Supplementary file to: Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial

Files

Steps to reproduce

Not applicable

Categories

Clinical Trial

Funding

Jiangsu Hengrui Pharmaceuticals

Licence